ACC 2021: ACTION Trial Shows Oral Anticoagulation with Rivaroxaban Does Not Help Patients With COVID-19
Late-breaking clinical trial results provide new insight into how to treat patients who are hospitalized with COVID-19 and at risk for blood clots. Findings from the ACTION trial, which was led by the Brazilian Clinical Research Institute in collaboration with DCRI’s Renato Lopes, MD, PhD, were presented by Lopes Sunday at the American College of Cardiology’s 70th annual Scientific Session & Expo. Results were also published after the conference in The Lancet.
ACC 2021: ADAPTABLE Answers the Aspirin Question, Provides Framework for Novel Research Methods
Results from a landmark clinical trial that sought to determine the safest and most effective dose of aspirin for patients with existing cardiovascular disease were presented Saturday morning as part of the 70th annual American College of Cardiology Scientific Session & Expo.
DCRI Strength in Building Networks Highlighted by Antibacterial Resistance Leadership Group Achievements
The Antibacterial Resistance Leadership Group (ARLG) involves over 100 experts, generating over 155 papers and initiating 55+ studies with 21,000 participants at 130 sites in 12 countries.
Study Shows Importance of Patient-Reported Outcomes in Heart Failure Care
More than twice as many patients saw changes in their patient-reported outcome measures compared with their traditional NYHA measures used by clinicians.
Pragmatic Approaches Enable Lower Burden and Cost in DCRI-led Trial
The HiLo study seeks to determine the optimal phosphate level for patients with chronic kidney disease.
Study Shows ‘Alarming Gaps’ in Treatment of Patients with Diabetes, Heart Disease
Over a third of patients with diabetes and heart disease were not taking any of the three therapies proven to prevent major adverse cardiovascular events.
New Study Analyzes Secondary COVID-19 Transmission for In-Person Schooling
The rate of transmission within schools was found to be much lower than the rate of community spread of the disease.
AHA 2020: AHA COVID Registry Sheds Light on Pandemic’s Impact on Racial Minorities
Two presentations on the American Heart Association COVID Registry shared data about COVID-19 hospitalizations collected from over 100 hospitals.
AHA 2020: RIVER Shows Rivaroxaban Safe for Patients with Bioprosthetic Valves
The study, which is the only randomized trial testing rixaroxaban in this patient population, builds on previous evidence established by the DCRI-led ROCKET-AF and ARISTOTLE studies.
AHA 2020: GALACTIC-HF Finds Investigational Therapy to be Effective
Patients assigned to the treatment, omecamtiv mecarbil, experienced a statistically significant difference in a composite endpoint of time to cardiovascular death or time to first heart failure event.